Several studies have emphasized the role of other specific lymphatic markers, including lymphatic vessel endothelial hyaluronic acid receptor 1 (LYVE-1), prospero homeobox 1 (Prox1), and podoplanin, as key regulators that facilitate a clear distinction between lymphatic and blood vessel invasion by breast cancer tumor cells [39,40]. Here, LYVE1 is linked to breast carcinoma.